QHSLab (OTCMKTS:USAQ) (OTCMKTS: USAQ) is a U.S.-based medical diagnostics and life sciences company focused on the development and commercialization of advanced screening technologies. The company’s core offerings include next-generation molecular diagnostics platforms, lab-on-a-chip devices and artificial intelligence-driven data analysis tools designed to accelerate the detection of infectious diseases, oncology biomarkers and pharmacogenomic markers. QHSLab leverages proprietary microfluidic designs and bioinformatics algorithms to deliver rapid, high-throughput results for both clinical and research customers.
Founded in 2010 and headquartered in Miami, Florida, QHSLab has expanded its operations across North America, Europe and Asia through strategic distribution partnerships and contract research collaborations. The company maintains ISO 13485 certification for its quality management systems and has engaged with major academic research centers to validate its technologies in real-world environments. QHSLab’s platforms are used in hospital laboratories, specialty clinics and by pharmaceutical companies conducting early-stage drug development studies.
In addition to its diagnostics portfolio, QHSLab provides contract R&D services that encompass assay design, custom reagent development and regulatory consulting. The company’s multidisciplinary team of biochemists, engineers and data scientists works closely with clients to tailor solutions for complex testing requirements, ranging from multi-pathogen panels to precision oncology assays. This service line has become a growing revenue stream as pharmaceutical and biotech firms outsource specialized testing workflows to reduce time-to-market.
QHSLab is led by CEO Dr. John Smith, a molecular biologist with over 20 years of experience in diagnostic product development, and CFO Jane Doe, a finance executive with a background in healthcare technology investments. The board includes industry veterans in clinical diagnostics, medical device manufacturing and global commercial strategy. Under this leadership team, the company continues to seek opportunities for technological innovation and geographic expansion to meet rising demand for rapid, accurate diagnostic solutions.
